8-K 1 abcl-8k_20210713.htm 8-K abcl-8k_20210713.htm

 

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________________

FORM 8-K

__________________________________________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 13, 2021

__________________________________________________

ABCELLERA BIOLOGICS INC.

(Exact name of registrant as specified in its charter)

__________________________________________________

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

British Columbia

 

001-39781

 

Not Applicable

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2215 Yukon Street

Vancouver, BC

 

 

 

 V5Y 0A1

(Address of registrant’s principal executive office)

 

 

 

(Zip code)

(604) 559-9005

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

__________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

 

 

 

 

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common shares

ABCL

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company  X

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

 

 


 


 

Item 8.01 Other Events.

On July 13, 2021, AbCellera Biologics Inc. (the “Company”), issued a press release titled “AbCellera Appoints Neil Berkley as Chief Business Officer.” A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.Description

99.1Press Release of AbCellera Biologics Inc. dated July 13, 2021



 


 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

 

Date: July 13, 2021

ABCELLERA BIOLOGICS INC.

 

 

 

 

By:

 

/s/ Carl L. G. Hansen

 

 

 

Carl L. G. Hansen, Ph.D.

 

 

 

Chief Executive Officer and Director

(Principal Executive Officer)